Catalyst Pharmaceutical


Analyst Predicts Success for Catalyst Pharmaceutical (CPRX ) Stock Following News of Latest FDA Approval

Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …

Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent Public Offering

Catalyst Pharmaceutical (NASDAQ: CPRX) is a company who develops therapeutic solutions for rare diseases. The company recently closed a previously announced public offering on …

Catalyst Bullish Stance Reiterated At Roth Capital Following 2Q14 Results

In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on shares of Catalyst Pharmaceutical (CPRX) with a $3.50 price target, following the company’s second-quarter results.

Roth Capital’s Scott Henry Maintains Buy On Catalyst Pharmaceutical Following Firdapse Phase 3 Completion

Catalyst Pharmaceutical (CPRX) announced Monday that the last patient has completed the blinded portion of the ongoing pivotal phase 3 study of Firdapse (amifampridine phosphate) …